Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00474630 · ClinicalTrials.gov registry record · Phase 3
A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes
A Phase 3 study of Obesity and Diabetes Mellitus, Type 2, sponsored by Orexigen Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 505
- Enrollment target
- 20
- Study locations
NCT00474630: Completed Phase 3 study of Obesity and Diabetes Mellitus, Type 2, sponsored by Orexigen Therapeutics.
NCT00474630 is a Phase 3 study of Obesity and Diabetes Mellitus, Type 2 that has completed, run by Orexigen Therapeutics. The registered enrollment target is 505 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (38% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00474630, a Phase 3 study of Obesity and Diabetes Mellitus, Type 2, has completed, sponsored by Orexigen Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 505 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is determine whether the combination of naltrexone SR and bupropion SR is safe and effective in treating obesity in subjects with type 2 diabetes.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Naltrexone SR 32 mg/bupropion SR 360 mg/ day
- BEHAVIORAL Ancillary therapy
Study Locations (20)
California
- Impact Clinical Trials - Beverly Hills
- Northern California Research - Carmichael
- Sierra Medical Research - Fresno
- Advance Clinical Research Institute - Orange
- Affiliated Research Institute - San Diego
- VA San Diego Healthcare System - San Diego
- Apex Research Institue - Santa Ana
Florida
- LCFP Inc. - Fort Myers
- Miami Research Associates - Miami
- Suncoast Clinical Research - Palm Harbor
- University Clinical Research - Pembroke Pines
Arizona
- Pivotal Research Centers - Peoria
- HOPE Research Institute - Phoenix
Indiana
- Deaconess Clinic - Evansville
- Northwest Indiana Center for Clinical Research - Valparaiso
Alabama
- SelfCenter, PC - Fairhope
Arkansas
- HealthStar Research - Hot Springs
Connecticut
- Chase Medical Research, LLC - Waterbury
Georgia
- CSRA Partners in Health, Inc - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 505 participants |
| Start Date | 2007-05 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
What the finished NCT00474630 record still lists
NCT00474630 is an interventional study that assigns participants to a tested intervention. The registered 505 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (38% lower).
The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00474630 names 20 study sites across 9 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT00474630 about?
NCT00474630 is a clinical study titled "A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes". The purpose of this study is determine whether the combination of naltrexone SR and bupropion SR is safe and effective in treating obesity in subjects with type 2 diabetes.
What is the current status of trial NCT00474630?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 505 participants. The study started on 2007-05. Estimated completion is 2009-06.
What conditions does trial NCT00474630 study?
This clinical trial studies the following conditions: Obesity, Diabetes Mellitus, Type 2, Overweight.
What interventions are being tested in trial NCT00474630?
The interventions under investigation include: Placebo (DRUG), Naltrexone SR 32 mg/bupropion SR 360 mg/ day (DRUG), Ancillary therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT00474630?
This trial is sponsored by Orexigen Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00474630 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00474630's enrollment target sits among peer trials
505 133rd of 1053 higher than 921 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05069428 · 506 participants · Phase 4
Delirium Reduction With Ramelteon
- NCT05797168 · 506 participants · Phase 1
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- NCT05846282 · 504 participants · NA
Students Rising Above: Offsetting the Health and Mental Health Costs of Resilience
- NCT06072131 · 504 participants · Phase 3
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia